R
Richard C. Chao
Researcher at Pfizer
Publications - 89
Citations - 5529
Richard C. Chao is an academic researcher from Pfizer. The author has contributed to research in topics: Sunitinib & non-small cell lung cancer (NSCLC). The author has an hindex of 23, co-authored 77 publications receiving 4390 citations. Previous affiliations of Richard C. Chao include Memorial Sloan Kettering Cancer Center & San Francisco VA Medical Center.
Papers
More filters
Journal ArticleDOI
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Eric Raymond,Laetitia Dahan,Jean-Luc Raoul,Yung-Jue Bang,Ivan Borbath,Catherine Lombard-Bohas,Juan W. Valle,Peter Metrakos,Denis Smith,Aaron I. Vinik,Jen-Shi Chen,Dieter Hörsch,Pascal Hammel,Bertram Wiedenmann,Eric Van Cutsem,Shem Patyna,Dongrui Ray Lu,C. Blanckmeister,Richard C. Chao,Philippe Ruszniewski +19 more
TL;DR: Continuous daily administration of sunitinib at a dose of 37.5 mg improved progression-free survival, overall survival, and the objective response rate as compared with placebo among patients with advanced pancreatic neuroendocrine tumors.
Journal ArticleDOI
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients
Jill Hallin,Lars D. Engstrom,Lauren Hargis,Andrew Calinisan,Ruth Aranda,David Briere,Niranjan Sudhakar,Vickie Bowcut,Brian R. Baer,Joshua Ballard,Michael Burkard,Fell Jay Bradford,John P. Fischer,Guy Vigers,Yaohua Xue,Sole Gatto,Julio Fernandez-Banet,Adam Pavlicek,Karen Velastagui,Richard C. Chao,Jeremy Barton,Mariaelena Pierobon,Elisa Baldelli,Emanuel F. Patricoin,Douglas P. Cassidy,Matthew A. Marx,Igor I. Rybkin,Melissa Lynne Johnson,Sai-Hong Ignatius Ou,Piro Lito,Kyriakos P. Papadopoulos,Pasi A. Jänne,Peter Olson,James G. Christensen +33 more
TL;DR: Comprehensive pharmacodynamic and pharmacogenomic profiling in sensitive and partially resistant non-clinical models identified mechanisms implicated in limiting anti-tumor activity including KRAS nucleotide cycling and pathways that induce feedback reactivation and/or bypass KRAS dependence.
Journal ArticleDOI
Institutional implementation of clinical tumor profiling on an unselected cancer population
Lynette M. Sholl,Khanh T. Do,Priyanka Shivdasani,Ethan Cerami,Adrian M. Dubuc,Frank C. Kuo,Elizabeth P. Garcia,Yonghui Jia,Phani K. Davineni,Ryan P. Abo,Trevor J. Pugh,Paul Van Hummelen,Aaron R. Thorner,Matthew D. Ducar,Alice H. Berger,Alice H. Berger,Mizuki Nishino,Katherine A. Janeway,Alanna J. Church,Marian H. Harris,Lauren L. Ritterhouse,Joshua D. Campbell,Vanesa Rojas-Rudilla,Azra H. Ligon,Shakti Ramkissoon,James M. Cleary,Ursula A. Matulonis,Geoffrey R. Oxnard,Richard C. Chao,V. Tassell,James J. Christensen,William C. Hahn,Philip W. Kantoff,David J. Kwiatkowski,Bruce E. Johnson,Matthew Meyerson,Levi A. Garraway,Levi A. Garraway,Geoffrey I. Shapiro,Barrett J. Rollins,Neal I. Lindeman,Laura E. MacConaill +41 more
TL;DR: Broad sequencing-based testing deployed across an unselected cancer cohort is feasible and contextual genomic features that may inform therapeutic response and examples where diagnoses revised by genomic profiling markedly changed clinical management are uncovered.
Journal ArticleDOI
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer
Mark A. Socinski,Silvia Novello,Julie R. Brahmer,Rafael Rosell,Jose Miguel Sanchez,Chandra P. Belani,Ramaswamy Govindan,James N. Atkins,Heidi H. Gillenwater,Cinta Pallares,L. Tye,Paulina Selaru,Richard C. Chao,Giorgio V. Scagliotti +13 more
TL;DR: Sunitinib has promising single-agent activity in patients with recurrent NSCLC, with an ORR similar to that of currently approved agents and an acceptable safety profile, and further evaluation in combination with other targeted agents and chemotherapy is warranted.
Journal ArticleDOI
Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III Trial
Giorgio V. Scagliotti,Maciej Krzakowski,Aleksandra Szczesna,János Strausz,A. Makhson,Martin Reck,Rafal Wierzbicki,Istvan Albert,Michael Thomas,Jose Elias Abrao Miziara,Z. Papai,Nina Karaseva,Sumitra Thongprasert,Elsa Dalmau Portulas,Joachim von Pawel,Ke Zhang,Paulina Selaru,L. Tye,Richard C. Chao,Ramaswamy Govindan +19 more
TL;DR: In patients with refractory NSCLC, sunitinib plus erlot inib did not improve OS compared with erlotinib alone, but the combination was associated with a statistically significantly longer PFS and greater ORR.